Browsing Tag
HARMONi-6
1 post
Ivonescimab plus chemotherapy cuts disease progression risk by 40% in first-line squamous NSCLC, outperforming PD-1 rival in Akeso’s HARMONi-6 trial
Find out how Akeso’s ivonescimab plus chemotherapy achieved a 40 % risk reduction over a PD-1 inhibitor combo in squamous NSCLC—and why it’s shaking up the global oncology market!